Residency · Residency · Plastic Surgery

Injectable Fillers and Neuromodulators

Introduction

Injectable fillers and neuromodulators represent the fastest-growing segment of aesthetic medicine, with over 15 million procedures performed annually in the United States. Neuromodulators (botulinum toxin) address dynamic rhytides caused by repetitive muscle contraction. Dermal fillers restore volume loss, correct static rhytides, and enhance facial contour. A thorough understanding of facial anatomy, product pharmacology, and injection techniques is essential for safe and effective outcomes.

Complications, though uncommon, can be devastating and include vascular occlusion with tissue necrosis and blindness.

Neuromodulators

Mechanism of Action

Botulinum toxin type A (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) inhibits acetylcholine release at the neuromuscular junction. Cleaves SNARE proteins (specifically SNAP-25) required for synaptic vesicle fusion. Results in temporary chemodenervation of the target muscle lasting 3-4 months. Onset of action: 2-5 days with peak effect at 2 weeks. Duration: 3-6 months depending on dose, muscle mass, and individual metabolism.

Common Treatment Areas

Glabellar complex: corrugator supercilii, procerus, and depressor supercilii; 20-30 units onabotulinumtoxinA. Forehead rhytides: frontalis muscle; 10-20 units; avoid complete paralysis to prevent brow ptosis. Lateral canthal lines (crow's feet): orbicularis oculi; 8-16 units per side. Masseter hypertrophy: 25-50 units per side for facial slimming and bruxism.

Platysmal bands: 2-5 units per injection point along the band. Hyperhidrosis: intradermal injection of 50-100 units per axilla.

Complications of Neuromodulators

Brow ptosis: from over-treatment of frontalis; treat conservatively, resolves in 2-4 weeks. Eyelid ptosis: from diffusion to levator palpebrae; treat with apraclonidine 0.5% drops (Muller's muscle stimulation). Lip incompetence: from treatment near the oral commissure; affects eating and speech. Antibody formation: rare; can cause treatment failure; more common with higher doses and frequent treatments.

<image>Anatomical illustration of the face showing the major muscles targeted by neuromodulator injection, including the frontalis, corrugator supercilii, procerus, orbicularis oculi, and platysma, with typical injection points and dosing marked</image>

Dermal Fillers

Classification by Material

Hyaluronic Acid Properties

Cross-linking (BDDE) increases resistance to enzymatic degradation and determines product longevity. G prime (G'): measure of filler stiffness; high G' fillers (Voluma) for deep structural support; low G' fillers (Volbella) for superficial fine lines. Cohesivity: ability to maintain shape under stress; important for projection and contouring. Hygroscopic properties: HA absorbs water, causing tissue expansion; important to avoid overcorrection. Duration ranges from 6-18 months depending on product, location, and individual metabolism.

Injection Techniques

Linear threading: antegrade or retrograde injection along a linear path. Serial puncture: multiple small bolus injections along a line. Fanning: single entry point with redirected passes in a fan shape. Cross-hatching: perpendicular linear threads for broad area coverage.

Bolus injection: deep depot placement for volume restoration (e.g., malar augmentation). Cannula technique: blunt-tipped cannula reduces vascular injury risk; preferred in high-risk areas.

Treatment by Facial Region

Midface/malar: deep bolus injection on periosteum; high G' HA or CaHA; 1-2 mL per side. Nasolabial folds: linear threading or fanning in deep dermis/subcutaneous plane; 0.5-1 mL per side. Lips: vermilion border definition and volume; low G' HA; 0.5-1.5 mL total. Marionette lines: linear threading from oral commissure to mandible; 0.5-1 mL per side.

Tear trough: superficial injection on orbicularis oculi or deep on periosteum; low-moderate G' HA; high-risk zone. Jawline and chin: deep supraperiosteal bolus; high G' products; 1-3 mL per side. Non-surgical rhinoplasty: dorsal augmentation and tip refinement; high-risk vascular territory.

<image>Cross-sectional diagram of facial soft tissue layers showing the correct depth of injection for different filler types: subcutaneous bolus for volumizing fillers, deep dermal placement for moderate fillers, and superficial dermal injection for fine-line fillers</image>

Vascular Anatomy and Danger Zones

Facial artery courses along the nasolabial fold, ascending to become the angular artery medial to the medial canthus. Supratrochlear and supraorbital arteries: at risk during glabellar and forehead injections. Ophthalmic artery anastomoses: retrograde flow from supratrochlear/dorsal nasal arteries can cause retinal artery occlusion and blindness. Highest-risk areas: glabella, nasal dorsum, nasolabial fold, and tear trough. The retro-orbicularis oculi fat (ROOF) and deep medial cheek fat pad are high-risk vascular zones.

Complications of Dermal Fillers

Vascular Compromise

Intravascular injection or external compression of vessels causes immediate blanching, pain, and livedo reticularis. Progression to tissue necrosis if untreated; classic distribution follows vascular territory (e.g., nasal alar necrosis from angular artery). Vision loss: most devastating complication; caused by retrograde arterial embolization to the ophthalmic artery. Immediate treatment protocol: stop injection, massage vigorously, apply warm compresses, inject hyaluronidase 200-600 units (for HA fillers), initiate aspirin, and consider hyperbaric oxygen.

For suspected retinal artery occlusion: emergent ophthalmology consultation; retrobulbar hyaluronidase injection may be attempted.

Other Complications

Tyndall effect: bluish discoloration from superficially placed HA; treat with hyaluronidase. Nodules and granulomas: inflammatory reaction to filler; treat with intralesional steroids, hyaluronidase, or excision. Biofilm and infection: late-onset inflammation; may require antibiotics, hyaluronidase, or surgical drainage. Migration: particularly with permanent fillers; can cause disfigurement years after injection. Delayed hypersensitivity: rare with HA; more common with PLLA and PMMA.

<image>Illustration of the periorbital and nasal vascular anatomy highlighting the ophthalmic artery, supratrochlear artery, dorsal nasal artery, and angular artery with labeled danger zones for filler injection</image>

Key Clinical Pearls

Always aspirate before injecting (though negative aspiration does not rule out intravascular placement); prefer slow injection with low pressure and small volumes. Use blunt cannulae in high-risk vascular zones (glabella, nose, tear trough) to reduce the risk of vascular injury. Keep hyaluronidase immediately available whenever injecting HA fillers; know the vascular compromise protocol. The "MD Codes" approach by Mauricio de Maio provides a systematic framework for facial assessment and injection planning. Avoid permanent fillers in most clinical scenarios due to the risk of long-term complications without reversibility.

References

1. Cavallini M, Gazzola R, Metalla M, Vaienti L. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J. 2013;33(8):1167-1174.
2. Carruthers JDA, Fagien S, Rohrich RJ, Weinkle S, Carruthers A. Blindness caused by cosmetic filler injection: a review of cause and therapy. Plast Reconstr Surg. 2014;134(6):1197-1201.
3. de Maio M. MD Codes: a methodological approach to facial aesthetic treatment with injectable hyaluronic acid fillers. Aesthetic Plast Surg. 2021;45(3):1035-1043. 4. Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90(3):168-175.

Read this lecture as Markdown